Lancet Oncology Lancet Oncology, Elsevier, 2018, 19 (8), pp.1117-1125. ⟨10.1016/S1470-2045(18)30333-4⟩ Oza, A M, Matulonis, U A, Malander, S, Hudgens, S, Sehouli, J, DelCampo, J M, Berton-Rigaud, D, Banerjee, S, Scambia, G, Berek, J S, Lund, B, Tinker, A V, Hilpert, F, Vázquez, I P, D'Hondt, V, Benigno, B, Provencher, D, Buscema, J, Agarwal, S & Mirza, M R 2018, ' Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA) : results from a double-blind, phase 3, randomised controlled trial ', The Lancet. Oncology, vol. 19, no. 8, pp. 1117-1125 . https://doi.org/10.1016/S1470-2045(18)30333-4